U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07486713) titled 'Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies' on March 12.
Brief Summary: A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Study Start Date: Feb. 23
Study Type: INTERVENTIONAL
Condition:
AML (Acute Myeloid Leukemia)
Glioma
Cholangiocarcinoma
Solid Tumor Malignancies
Intervention:
DRUG: Olutasidenib
Participants will receive repeated dosing of olutasidenib from Day 5 to Day 22 until steady state, with an option to continue t...